Clinical trial
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT04994483
Study timeline
Study start (actual)2021-11-03Date precision: day
Registry last updated2025-05-25
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Alzheimer Diseaseunresolved
Interventions
Sponsors & collaborators
Cassava Sciences, Inc.lead sponsor
Premier Researchcollaborator
Mapped research locations
MiamiFlorida, United States3DallasTexas, United States2TampaFlorida, United States2OrlandoFlorida, United States2AustinTexas, United States2SherbrookeQuebec, Canada2New YorkNew York, United States1SeattleWashington, United States1PortlandOregon, United States1PhoenixArizona, United States1JacksonvilleFlorida, United States1DenverColorado, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04994483 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.